It is unclear what impact pheromonotherapy has on stress in dogs in shelter environments
a Knowledge Summary by
Tighearnan F. Mooney BVMSci (Hons) MRCVS 1*
1Veterinary School Main Building, University of Surrey, Daphne Jackson Road, Guildford, GU2 7AL
*Corresponding Author (tfmooneymrcvs@gmail.com)
Vol 5, Issue 2 (2020)
Published: 19 Jun 2020
Reviewed by: Laura Dixon (PhD BSc) and Debbie Emmerson (MSc)
Next review date: 31 Jan 2021
DOI: 10.18849/VE.V5I2.278
In dogs in shelters does pheromonotherapy reduce stress compared to untreated dogs?
Clinical bottom line
Category of research question
Treatment
The number and type of study designs reviewed
Two studies were evaluated, one was a prospective blinded randomised placebo-controlled study (Tod et al., 2005) and the other was a prospective unblinded repeated measures study
Strength of evidence
The papers evaluated provide a weak-to-moderate strength of evidence, due to the limited sample size and short duration of the intervention
Outcomes reported
In both studies pheromonotherapy resulted in a statistically significant reduction in mean bark amplitude but not in duration or peak bark amplitude. Neither study found a significant change in expression of fear-related behaviours in response to a neutral stranger or a stressor
Conclusion
Based on the studies assessed in this Knowledge Summary it is not possible to determine if pheromonotherapy reduces stress in dogs in shelter environments. It cannot be determined whether the small absolute reduction in bark amplitude present in both studies is clinically or biologically significant. Additionally, barking is a non-specific behaviour (Protopopova, 2016; Pongráczet al., 2010; Taylor & Mills, 2007; and Yin, 2002), so these results cannot be interpreted as a reduction in stress without further study.
It is beyond the scope of this Knowledge Summary to comment on any perceived or apparent difference in the effectiveness of pheromonotherapy in the shelter environment compared to the home environment
How to apply this evidence in practice
The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources.
Knowledge Summaries are a resource to help reinforce or inform decision-making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care.
Clinical scenario
A healthy young dog has been bought into a shelter by a member of the public, it is obvious that the animal is owned however the owner cannot be identified or contacted. The shelter has decided that the dog would be suitable for adoption if unclaimed by the owner, and as such it has been placed into the shelter’s kennels while attempts are made to locate the owner. The dog quickly becomes distressed, frequently displaying avoidance and displacement behaviours. You are in charge of the case and believe that the dog requires pharmacological intervention to reduce stress, the only option available to you is pheromonotherapy which you have used successfully in owned animals, however, you remember reading a metanalysis where the efficacy of pheromonotherapy in shelter settings was questioned (Frank et al., 2010).
The evidence
The systematic literature search identified two prospective studies which directly address the PICO question. One is a blinded randomised placebo-controlled study with a sample size of 54 dogs (Tod et al., 2005), in terms of study design and sample size this is the stronger of the two papers, and was the only relevant study included in Frank et al.’s (2010) metanalysis. The other study is a repeated measures study with a sample size of 25 dogs (Hermiston et al., 2018). Neither paper is very powerful due to the small sample size and short duration of interventions.
Summary of the evidence
Population: | Dogs present in a Scottish animal shelter – not undergoing behavioural therapy, psychopharmacological intervention, or less than 6 months old. 22/54 participants were mongrels, the remaining 32 participants were classified into 9 breed types (Pointer, German Shepard Dog type, Terrier type, Labrador type, Staffordshire bull, Dalmatian type, Jack Russell, Collie cross, and Border Collie type). More male dogs were enrolled than female (34 compared to 20), reflecting the intake population at the shelter. The ages of participants were not controlled for as the information was often not available or accurate |
Sample size: | n = 54 dogs |
Intervention details: |
|
Study design: | Blind, randomised, placebo-controlled design |
Outcome Studied: |
|
Main Findings (relevant to PICO question): |
|
Limitations: |
|
Population: | Stray or relinquished dogs present in an English animal shelter. 12 of the 25 participants were cross or mixed breeds, the remaining 13 participants were classified as purebred (Labrador, Great Dane, Springer spaniel, Deerhound, Husky, Akita, Collie, and Staffordshire Bull Terrier). More male dogs (16/25) were enrolled than bitches (9/25). Ages varied from 5 months to 168 months with a mean of 41.64 months |
Sample size: | n = 25 dogs |
Intervention details: |
|
Study design: | Repeated measures design |
Outcome Studied: | Whether pheromonotherapy reduces:
|
Main Findings (relevant to PICO question): |
|
Limitations: |
|
Appraisal, application and reflection
According to BSAVA (2017), Adaptil®, formally branded as D.A.P®, (Ceva Santé Animale) is the only pheromone-based product on general sale in the UK for use in dogs. It is therefore unsurprising that although neither of the studies reviewed was supported by Ceva both used Adaptil® products as their interventions. Ceva published comprehensive references which support Adaptil’s® efficacy in various settings (Ceva Santé Animale, 2015). Of the two studies Ceva cites to support Adaptil’s® use in a shelter setting, one was assessed in this Knowledge Summary (Tod et al., 2005), the other was excluded from assessment because it was only published as part of a conference proceeding. The study (Barlow & Goodwin, 2009) was a double-blind placebo-controlled trial of Dog Appeasing Pheromone (D.A.P®) infused collars, total sample size was 90 dogs (31 treated collars, 29 placebo collars, 30 controls with no collars) and lasted 10 days. If it had been included this study would have had the largest sample size and longest duration, its results could have added power to the conclusions drawn in this Knowledge Summary, however as the study was published in short form, its methodology was not described in detail and it was not possible to evaluate and critique the paper to the degree necessary for inclusion in a Knowledge Summary.
In the two studies reviewed the dogs were exposed to pheromonotherapy for 30 minutes (Hermiston et al., 2018) and 7 days (Tod et al., 2005), both of which are consistent with the onset of actions advertised by Ceva (Adaptil® transport spray should act ‘almost immediately’ whilst the Adaptil® diffuser should be fully functional within 24 hours (Ceva Santé Animale, 2020)). However, the study durations are short when compared to the 7–21 days target overall length of stay in American shelters (UC Davis Koret Shelter Medicine Programme, 2017) and that Brown et al. (2013) found that the average length of stay for an adult dog in a no-kill shelter is 42 days. This is significant as the interventions applied do not reflect the realities that dogs experience, so these studies cannot accurately predict what impact pheromonotherapy will have in a shelter environment. Additionally, although both studies identified statistically significant reductions in barking amplitude, neither study was able to establish if this reduction was clinically relevant.
Sales et al. (1997) showed that barking has a negative impact on welfare, therefore using barking as part of a composite measure for welfare could be justified. However, barking is also a non-specific behaviour indicative of elevated arousal not stress, fear, or welfare specifically (Protopopova, 2016; and Yin, 2002), which may be socially motivated in shelter environments (Taylor & Mills, 2007). Additionally, barking behaviours and motivation may have a breed specific component (Pongrácz et al., 2010) which was not controlled for in these studies. Therefore, without further research into the emotional motivations for barking the use of barking amplitude, frequency, or duration as a proxy measure for stress is a limitation for the studies assessed.
Finally, excessive vocalisation was not included in the quality of life assessment tool developed by Kiddie & Collins (2014) because in a shelter or kennel environment dogs are rarely in auditory or visual isolation which may emphasise the aforementioned social component which can motivate barking. For these reasons future studies may gain more insight into the emotional status of dogs in shelter environments if they chose to assess factors included in the validated quality of life assessment tool.
Methodology Section
Search Strategy | |
Databases searched and dates covered: |
|
Search strategy: | [dog OR dogs OR cani*] AND pheromones AND [stress OR behavio?r] AND shelter |
Dates searches performed: | 31/01/2019 |
Exclusion / Inclusion Criteria | |
Exclusion: |
|
Inclusion: | Must discuss the impact of pheromonotherapy on stress in dogs in a shelter setting |
Search Outcome | ||||||
Database |
Number of results |
Excluded – No shelter |
Excluded – No pheromonotherapy stress intervention |
Excluded – No canine |
Excluded – Case study, guidance, policy, conference proceeding, or correspondence |
Total relevant papers |
CAB Abstracts |
10 | 4 | 2 | 0 | 2 | 2 |
UK-Vet |
8 | 3 | 1 | 4 | 0 | 0 |
Scopus |
35 | 13 | 15 | 5 | 0 | 2 |
PubMed |
1 | 1 | 0 | 0 | 0 | 0 |
Medline |
2 | 1 | 1 | 0 | 0 | 0 |
Web of Science |
19 | 6 | 8 | 0 | 3 | 2 |
Total relevant papers when duplicates removed |
2 |
The author declares no conflicts of interest.
Intellectual Property Rights
Authors of Knowledge Summaries submitted to RCVS Knowledge for publication will retain copyright in their work, and will be required to grant to RCVS Knowledge a non-exclusive licence to publish including but not limited to the right to publish, re-publish, transmit, sell, distribute and otherwise use the materials in all languages and all media throughout the world, and to licence or permit others to do so.
Disclaimer
Knowledge Summaries are a peer-reviewed article type which aims to answer a clinical question based on the best available current evidence. It does not override the responsibility of the practitioner. Informed decisions should be made by considering such factors as individual clinical expertise and judgement along with patient’s circumstances and owners’ values. Knowledge Summaries are a resource to help inform and any opinions expressed within the Knowledge Summaries are the author's own and do not necessarily reflect the view of the RCVS Knowledge. Authors are responsible for the accuracy of the content. While the Editor and Publisher believe that all content herein are in accord with current recommendations and practice at the time of publication, they accept no legal responsibility for any errors or omissions, and make no warranty, express or implied, with respect to material contained within. For further information please refer to our Terms of Use.